Target enzyme mutations are the molecular basis for resistance towards pharmacological inhibition of nicotinamide phosphoribosyltransferase

BACKGROUND: Inhibitors of nicotinamide phosphoribosyltransferase (NAMPT) are promising cancer drugs currently in clinical trials in oncology, including APO866, CHS-828 and the CHS-828 prodrug EB1627/GMX1777, but cancer cell resistance to these drugs has not been studied in detail. METHODS: Here, we...

Descripción completa

Detalles Bibliográficos
Autores principales: Olesen, Uffe H, Petersen, Jakob G, Garten, Antje, Kiess, Wieland, Yoshino, Jun, Imai, Shin-Ichiro, Christensen, Mette K, Fristrup, Peter, Thougaard, Annemette V, Björkling, Fredrik, Jensen, Peter B, Nielsen, Søren J, Sehested, Maxwell
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2010
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3019212/
https://www.ncbi.nlm.nih.gov/pubmed/21144000
http://dx.doi.org/10.1186/1471-2407-10-677

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3019212/
https://www.ncbi.nlm.nih.gov/pubmed/21144000
http://dx.doi.org/10.1186/1471-2407-10-677

Ejemplares similares